Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U6 small nuclear RNA pseudogenes, such as RNU6-119P, are processed genomic sequences derived from the U6 snRNA gene. U6 snRNA itself is an essential component of the spliceosome and is involved in coordinating catalytic reactions required for intron removal during pre-mRNA processing[2][3]. Pseudogenes like RNU6-119P arise through retrotransposition events—often mediated by LINE elements—resulting in non-functional genomic copies[1][4]. These pseudogenes are prevalent throughout the genome and can serve as markers for retrotranspositional activity. However, they do not encode functional RNA molecules and have no direct role as therapeutic targets, biological regulators, or disease markers[4]. In summary, RNU6-119P designates a noncoding, processed pseudogene derived from U6 small nuclear RNA. While U6 snRNA itself is critical for intron splicing in eukaryotes, its pseudogenes, including RNU6-119P, do not contribute to cellular activities and are not considered targets for therapeutic intervention[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 119 pseudogene (RNU6-119P).